HR and breast cancer: The postMONARCH trial is a global, phase 3, randomized, placebo-controlled study designed to evaluate the efficacy of abemaciclib plus fulvestrant in patients with HR+, HER2− advanced breast cancer and disease progression on prior CDK4/6 inhibitor plus endocrine therapy (NCT05169567).